Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 2, 1999, Pages 166-172

  De La Serna, Gaspar ^a,b,c   Cadarso, Carmen ^a,b  

^a Primary Care Center Benigànim   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c Centro de Salud San José   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; RESIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032765965     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.99709     Document Type: Article

References (28)

1. 1. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311:501-5.
2. 2. Stone MC, Thorp JM. Plasma fibrinogen: a major coronary risk factor. J R Coll Gen Pract 1985;35:565-9.
3. 3. Meade TW Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
4. 4. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987;258:1183-6.
5. 5. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991;83:836-44.
6. 6. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM Study in healthy men [Published correction appears in Arterioscler Thromb 1994;14:1392]. Arterioscler Thromb 1994;14:54-9.
7. 7. Cremer P, Nagel D, Böttcher B, Seidel D. Fibrinogen: ein koronarer Risikofactor. Diagnose Labor 1992;42:28-35.
8. 8. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
9. 9. de la Serna G. Fibrinogen: a new major risk factor for cardiovascular disease. A review of the literature. J Fam Pract 1994;39:468-77.
10. 10. International Task Force. Prevention of Coronary Heart Disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society. Nutr Metab Cardiovasc Dis 1992;2:113-56.
11. 11. Leschke M, Mecklenbeck W, Schöbel F, Strauer BE. Intermittent urokinase therapy in patients to therapy. In: Ernst E, Koenig W, Lowe G, Meade T, editors. Fibrinogen: a "new" cardiovascular risk factor. Vienna: Blackwell; 1992. p. 434-9.
12. 12. Leschke M, Schoebel FC, Strauer BE. Long-term follow-up in chronic-intermittent urokinase therapy in patients with refractory angina pectoris [abstract]. Blood Coagul Fibrinolysis 1994;5(suppl 2):17.
13. 13. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993;70:241-3.
14. 14. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994;154:441-9.
15. 15. Castelluccio A, Bologna E. Effect of sulodexide on blood viscosity in patients with peripheral vascular disease. Curr Med Res Opin 1991;12:325-31.
16. 16. Lunetta M, Salanitri T. Lowering of plasma viscosity by oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease. J Int Med Res 1992;20:45-53.
17. 17. Crepaldi G, Fellin R, Calabró A, Rossi A, Ventura A, Mannarino E, et al. Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan: current therapeutic effects and perspectives for clinical use. Atherosclerosis 1990;81:233-43.
18. 18. Reaven GM. Role of insulin resistance in human disease (Syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31.
19. 19. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998;352:670-1.
20. 20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
21. 21. Lienart F, Morissens M, Jacobs P, Ducobu J. Doxycycline and hepatotoxicity. Acta Clin Belg 1992;47:205-8.
22. 22. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53.
23. 23. MAAS investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
24. 24. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, et al. Effect of lipid lowering by pravastatin on progression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91: 2528-40.
25. 25. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoproteins subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994;5:395-403.
26. 26. Frick MH, Elo O, Haapa K, Heinomen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
27. 27. Assmann G, Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-7.
28. 28. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen O, et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.